This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Aska Pharmaceutical Co., Ltd.. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Norimichi Okubo: Innovator in Pharmaceutical Composition
Introduction
Norimichi Okubo is a notable inventor based in Kawasaki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid dispersions that enhance the solubility and bioavailability of active ingredients.
Latest Patents
Okubo holds a patent for a "Solid dispersion and pharmaceutical composition of the same, and production processes thereof." This invention involves a powdery porous carrier that is impregnated with a solution containing an organic solvent and an active ingredient that is hardly soluble in water. The process allows for the creation of a solid dispersion that supports the active ingredient without the need for supercritical fluid treatment. The porous silicon-containing carrier used in this invention has specific properties, including a heating loss of not more than 4% by weight at a temperature of 950°C for 2 hours. This innovation is particularly beneficial for improving the solubility and bioavailability of compounds such as fibrates.
Career Highlights
Norimichi Okubo is associated with Aska Pharmaceutical Co., Ltd., where he has been instrumental in advancing pharmaceutical technologies. His work has led to the development of formulations that can significantly improve the effectiveness of medications.
Collaborations
Okubo has collaborated with notable colleagues, including Hashime Kanazawa and Kazushi Yoshida. Their combined expertise has contributed to the successful development of innovative pharmaceutical solutions.
Conclusion
Norimichi Okubo's contributions to the field of pharmaceuticals through his innovative patent demonstrate his commitment to enhancing drug formulations. His work continues to impact the industry positively, paving the way for improved therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile